Ismail Ismailoglu, PhD
Minneapolis, Minnesota, United States
2K followers
500+ connections
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Licenses & Certifications
Volunteer Experience
-
Volunteer Leader
New York Road Runners
- 4 years 1 month
- Direct up to 20 volunteers at NYRR races, including the NYC Marathon and NYC Half.
- Communicate with NYRR team and the volunteers about the group's duties for the day. Respond to problems as they arise.
- Co-lead weekly Astoria Park OpenRun's that are regularly attended by 30-40 runners. -
Project Leader | Consultant
The Solution Lab, Inc.
- 3 months
- Led team of 4 consultants, which was retained by a financial firm to analyze the competitive landscape in an emerging life sciences market.
- Covered an industry conference to provide the client with up-to-date information.
- Oversaw the development of a white paper summarizing the team's findings and recommendations which was published by the client to guide members’ investment strategy in the rapidly growing sector. -
Board Member
Weill Cornell Medical College - Postdoctoral Association
- 1 year 4 months
Science and Technology
-
Board Member
Rockefeller University - Postdoctoral Association
- 1 year 2 months
Science and Technology
● Communicated with researchers and worked with administration to find solutions for their issues.
● Organized professional and social events.
-
Instructor
Bilkent University
- 1 year 10 months
Children
● Worked as an instructor at Bilkent University's Computer Literacy courses for underprivileged high school students.
Courses
-
From Scientist to CSO (NYAS)
-
-
Fundamentals of the Bioscience Industry Program
-
-
Inspiring Leadership Through Emotional Intelligence (Coursera)
-
-
Model Thinking (Coursera)
-
Projects
-
Pro bono consulting project: Skill Assessment team
-
• Member of Assessment Team at Oystir (NY-based startup Venture spearheaded by McKinsey Consultants)
• Analyzed survey data
• Developed survey questions to assess skills of PhDs for job matching purposesOther creators -
-
Fundamentals of Bioscience Industry Program Project - Evaluation of Juno Therapeutics
-
• Evaluated CD19 CAR-T technologies and intellectual property held by Juno Therapeutics
• Determined competitors in CAR-T immunotherapy field
• Evaluated manufacturing and regulatory concerns associated with CAR-T therapeutics
• Developed a market model for B-cell indications targeted by Juno Therapeutics to facilitate revenue projections
Other creators -
Languages
-
English
Native or bilingual proficiency
-
Turkish
Native or bilingual proficiency
-
German
Elementary proficiency
Other similar profiles
Explore more posts
-
QuantHealth
AI is making waves in clinical trials, from predicting patient treatment response to creating digital trial participants, and beyond. Allison DeAngelis sheds light on how companies like QuantHealth are utilizing AI to improve the clinical trial process in an insightful new STAT article. https://lnkd.in/e9dDKiZr
1 Comment -
Malvika Verma Miller, Ph.D.
🌟 Exciting advancements across two of my favorite topics: cell therapy and drug delivery! 🧬💊 A new review article published in Nature Portfolio explores how integrating drug delivery systems at various scales can enhance cell therapies' efficacy and safety. By optimizing pharmacokinetics, cell function, and viability, and preventing cell exhaustion and immunogenicity, these innovations pave the way for smarter, more effective treatments. The development of adaptive drug delivery systems and novel biomaterials for cell encapsulation promises to overcome current challenges and drive clinical translation. Check out the full article here: https://lnkd.in/ea6dirNT #CellTherapy #DrugDelivery #Biotech #Pharmaceuticals #Innovation
-
Dubai Future Forum
One more day to go! Join us for a conversation with Friend of the Forum Jamie Metzl about the big picture implications of the intersecting AI, genetics, and biotechnology revolutions and a celebration of his book Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. Register here: https://lnkd.in/d9_CK8pe
-
BioPharmaTrend.com
In latest Weekly Tech+Bio Highlights, we take a look at: • How to Differentiate Hype from Substance in the AI Drug Discovery Space? Dr. Alex Zhavoronkov of Insilico Medicine outlines ten questions to evaluate AI drug discovery companies, focusing on clinical progress, target novelty, and financial stability. • How to Define Intelligence and Consciousness for In Silico and Organoid-based Systems? A global initiative led by Cortical Labs seeks to standardize definitions for intelligent systems across disciplines using a collaborative Delphi method. • GSK, Flagship Partner for Drug Discovery GSK partners with Flagship Pioneering to develop up to ten new drugs and vaccines, potentially generating over $7 billion for Flagship and its companies. • 3D-Printing mRNA Vaccines Triastek, Inc. and BioNTech SE collaborate to develop 3D-printed oral RNA therapeutics, optimizing delivery and absorption across the gastrointestinal mucosa. • The New Milestone for Regenerative Medicine Magellan Stem Cells' allogeneic mesenchymal stem cell therapy, MAG200, shows significant efficacy in Phase I/II trials for knee osteoarthritis, improving pain and cartilage quality. • 12 Emerging Neurotech Startups to Keep an Eye On in 2024 A list of promising neurotech startups, including Arctop, Diagnostic Biochips, Inc., Neurable, and more, developing innovative technologies in brain-computer interfaces and cognitive health. Upcoming event: Join us at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) will be held on August 26-30 in Copenhagen, Denmark! For a more comprehensive review in our weekly rubric, see the link in the comments.
8 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More